STOCK TITAN

Assembly Biosciences (ASMB) CEO receives 50,750 RSUs in equity grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

ASSEMBLY BIOSCIENCES, INC. CEO and President Jason A. Okazaki received a grant of 50,750 shares of common stock in the form of restricted stock units at no cash cost. These RSUs were approved on March 29, 2026 and became issuable after stockholders approved an amendment to the company’s 2018 Stock Incentive Plan on June 4, 2026.

The RSUs vest in four approximately equal annual installments on March 29, 2027, 2028, 2029, and 2030, subject to continued service. After this award, Okazaki directly holds 163,354 shares of common stock, including 688 shares acquired through the company’s Employee Stock Purchase Plan on May 14, 2026.

Positive

  • None.

Negative

  • None.
Insider Okazaki Jason A
Role CEO and President
Type Security Shares Price Value
Grant/Award Common Stock 50,750 $0.00 --
Holdings After Transaction: Common Stock — 163,354 shares (Direct, null)
Footnotes (1)
  1. Restricted stock units ("RSUs") representing 35% of the reporting person's annual equity grant, which was approved on March 29, 2026 and was contingent upon stockholder approval of an amendment to the Issuer's Amended and Restated 2018 Stock Incentive Plan (the "Plan") that increased the number of shares of common stock authorized for issuance under the Plan (the "Plan Amendment"). Although the RSUs were granted on March 29, 2026, the RSUs became issuable upon stockholder approval of the Plan Amendment on June 4, 2026 and vest in four approximately equal installments, assuming continuous service on each vesting date, as follows: March 29, 2027; March 29, 2028; March 29, 2029; and March 29, 2030. Includes 688 shares acquired under the Assembly Biosciences, Inc. Second Amended and Restated 2018 Employee Stock Purchase Plan on May 14, 2026.
RSUs granted 50,750 shares Restricted stock units granted March 29, 2026
Grant price $0.00 per share RSU award to CEO Jason A. Okazaki
Post-grant holdings 163,354 shares Total common stock held directly after transaction
ESPP shares included 688 shares Acquired under Employee Stock Purchase Plan on May 14, 2026
Vesting schedule 4 annual installments Vesting on March 29, 2027, 2028, 2029, 2030
Plan approval date June 4, 2026 Stockholders approved amendment to 2018 Stock Incentive Plan
Restricted stock units ("RSUs") financial
"Restricted stock units ("RSUs") representing 35% of the reporting person's annual equity grant"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
annual equity grant financial
"RSUs representing 35% of the reporting person's annual equity grant, which was approved on March 29, 2026"
Amended and Restated 2018 Stock Incentive Plan regulatory
"amendment to the Issuer's Amended and Restated 2018 Stock Incentive Plan (the "Plan")"
Plan Amendment regulatory
"authorized for issuance under the Plan (the "Plan Amendment")"
Employee Stock Purchase Plan financial
"Includes 688 shares acquired under the Assembly Biosciences, Inc. Second Amended and Restated 2018 Employee Stock Purchase Plan"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Okazaki Jason A

(Last)(First)(Middle)
C/O ASSEMBLY BIOSCIENCES, INC.
TWO TOWER PLACE, 7TH FLOOR

(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
ASSEMBLY BIOSCIENCES, INC. [ ASMB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
CEO and President
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
03/29/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock03/29/2026A50,750(1)A$0163,354(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Restricted stock units ("RSUs") representing 35% of the reporting person's annual equity grant, which was approved on March 29, 2026 and was contingent upon stockholder approval of an amendment to the Issuer's Amended and Restated 2018 Stock Incentive Plan (the "Plan") that increased the number of shares of common stock authorized for issuance under the Plan (the "Plan Amendment"). Although the RSUs were granted on March 29, 2026, the RSUs became issuable upon stockholder approval of the Plan Amendment on June 4, 2026 and vest in four approximately equal installments, assuming continuous service on each vesting date, as follows: March 29, 2027; March 29, 2028; March 29, 2029; and March 29, 2030.
2. Includes 688 shares acquired under the Assembly Biosciences, Inc. Second Amended and Restated 2018 Employee Stock Purchase Plan on May 14, 2026.
/s/ John O. Gunderson, as Attorney-in-Fact06/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did ASMB CEO Jason Okazaki receive in this insider transaction?

Jason Okazaki received 50,750 restricted stock units of Assembly Biosciences common stock as part of his annual equity grant. The RSUs were granted at no cash cost and are a compensation award rather than an open-market share purchase or sale.

When do Jason Okazaki’s new ASMB restricted stock units vest?

The 50,750 restricted stock units granted to Jason Okazaki vest in four approximately equal annual installments. Vesting dates are March 29, 2027, March 29, 2028, March 29, 2029, and March 29, 2030, assuming he continues to provide service through each vesting date.

What approval was required for Jason Okazaki’s ASMB RSU award?

The RSU award depended on stockholders approving an amendment to Assembly Biosciences’ Amended and Restated 2018 Stock Incentive Plan. This amendment increased shares authorized under the plan and was approved on June 4, 2026, after which the RSUs became issuable to Okazaki.

How many ASMB shares does Jason Okazaki hold after this grant?

Following the RSU grant, Jason Okazaki directly holds 163,354 shares of Assembly Biosciences common stock. This total includes 688 shares acquired through the company’s Second Amended and Restated 2018 Employee Stock Purchase Plan on May 14, 2026.

Are Jason Okazaki’s ASMB RSUs an open-market purchase or sale?

The RSUs are a compensation award, not an open-market trade. They were granted at a price of $0.00 per share as part of his annual equity grant, contingent on stockholder approval of additional shares under the company’s stock incentive plan.